FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,400 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $46.81, for a total transaction of $861,304.00. Following the sale, the chief executive officer now directly owns 2,550,176 shares of the company’s stock, valued at approximately $119,373,738.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
FibroGen stock opened at $47.21 on Monday. The firm has a market capitalization of $4.04 billion, a price-to-earnings ratio of -45.83 and a beta of 1.72. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.75 and a quick ratio of 7.75. FibroGen Inc has a 12 month low of $37.27 and a 12 month high of $68.55.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.40. The firm had revenue of $108.05 million during the quarter, compared to the consensus estimate of $72.15 million. FibroGen had a negative net margin of 40.58% and a negative return on equity of 16.84%. The firm’s revenue was up 251.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.27) earnings per share. On average, analysts anticipate that FibroGen Inc will post -0.97 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on FGEN shares. Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $62.00 price target for the company in a research report on Friday, March 8th. Piper Jaffray Companies started coverage on shares of FibroGen in a research report on Friday, April 12th. They set a “neutral” rating and a $65.00 price target for the company. Stifel Nicolaus started coverage on shares of FibroGen in a research report on Monday, February 11th. They set a “buy” rating and a $71.00 price target for the company. BidaskClub raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. Finally, TheStreet raised shares of FibroGen from a “d+” rating to a “c-” rating in a research report on Friday, March 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $71.17.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/22/fibrogen-inc-fgen-ceo-sells-861304-00-in-stock.html.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Further Reading: What is a balanced fund?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.